pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
910
stories
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Stealthy startup Treeline plans a reverse merger
biopharma dive
Jun 9, 26
Trump administration warns more than 500 hospitals to provide more price information or face fines
stat
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 9, 26
Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
endpoints
Jun 9, 26
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
stat
Jun 9, 26
GSK boosts cancer pipeline with $11B Nuvalent buyout
biopharma dive
Jun 9, 26
STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
stat
Jun 9, 26
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
stat
Jun 9, 26
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
endpoints
Jun 9, 26
Alcohol study discarded by Trump officials is published in scientific journal
stat
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
Roche stakes $700M on Nurix’s protein-degrading drug
biopharma dive
Jun 8, 26
Tango data add to growing momentum for pancreatic cancer drugs
biopharma dive
Jun 8, 26
Incyte to buy blood disorder drug in possibly $2B deal
biopharma dive
Jun 8, 26
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
biopharma dive
Jun 8, 26
J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
endpoints
Jun 8, 26
Tango plans Phase 3 pancreatic cancer study after combo success
endpoints
Jun 8, 26
STAT+: Novo underwhelmed by drug it once fought Pfizer for
stat
Jun 8, 26
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
stat
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 8, 26
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
stat
Jun 8, 26
Precision under pressure: Logistic solutions for nuclear medicine scalability
biopharma dive
Jun 7, 26
STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
stat
Jun 6, 26
STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
stat
Jun 6, 26
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
stat
Jun 6, 26
Opinion: How the Amish think about vaccines, health care costs, and much more
stat
Jun 6, 26
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
stat
Jun 5, 26
Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
endpoints
Jun 5, 26
Opinion: If Americans risk their lives fighting Ebola overseas, they deserve the right to come home
stat
← prev
page 18 of 31
next →
